Tarsus Pharmaceuticals, Inc. 8-K

What Happened

• On May 6, 2026, Tarsus Pharmaceuticals, Inc. announced its results of operations for the three months ended March 31, 2026 via a press release. The press release is attached to the company's Form 8-K as Exhibit 99.1 and the 8-K furnishes this information under Item 2.02 (Results of Operations and Financial Condition). The report was signed by Chief Financial Officer and Chief Strategy Officer Jeffrey Farrow.

Key Details

• Press release date: May 6, 2026.
• Reporting period: three months ended March 31, 2026 (Q1 2026).
• Disclosure furnished under Item 2.02 and attached as Exhibit 99.1 to the Form 8-K.
• Form 8-K signed by CFO/CSO Jeffrey Farrow on behalf of the company.

Why It Matters

• The company’s quarterly results (earnings, revenue, cash position and related commentary) are material to investors and may affect analyst estimates and the stock price. Because the 8-K furnishes the press release rather than filing it, investors should review Exhibit 99.1 for the specific financial figures, any commentary on trends or guidance, and compare those details to prior quarters and market expectations.